Friday, 21 Sep 2018

You are here

Do JAK Inhibitors Increase the Risk of Venous Thromboembolic Events?

Drug Safety has published a systematic review of the FDA’s Adverse Event Reporting System (FAERS) and finds numerous reports of thromboembolic adverse events (AEs) associated with two currently marketed Janus kinase (JAK) inhibitors, tofacitinib (Xeljanz) and ruxolitinib (Jakafi). (Citation source: https://buff.ly/2zXyY2X)

The issue was recently brought to the forefront when the FDA issued a complete response letter to Lilly because of an  "imbalance in thromboembolic events" (VTE) seen with their JAK 1 inhibitor,  baricitinib (but not with placebo) in their rheumatoid arthritis (RA) development trials. 

Baricitinib is currently approved in the European Union, Japan, Switzerland and Kuwait, where the small risk of thromboembolic events is listed under drug safety in the product label. 

There is no warning or risk of thromboembolic events in the current product label for either tofacitinib (Xeljanz) and ruxolitinib (Jakafi). 

Multiple reports have shown that RA patients (and many other autoimmune and inflammatory diseases) have a higher risk of VTE (http://buff.ly/2tAHGRO) that is unrelated to the use of DMARDs or TNF inhibitors. Multiple studies have shown that the risk of VTE in RA is about 5-6 VTE per 1000 person years. (http://buff.ly/2tAEu8t). 

To further assess the risk with tofacitinib and ruxolitinib, researchers queried the Medwatch FEARS database and only included those VTE events where the drug was listed as the “primary suspect” for the AE.

The following events were identified:

  • Pulmonary thrombosis: 18 unique cases for tofacitinib (16 resulted in hospitalization), 9 for ruxolitinib (all resulted in hospitalization, and 2 deaths are suspected to be linked), 3 for extended-release tofacitinib (all resulted in hospitalization).
  • Pulmonary embolism: 36 unique cases for tofacitinib (25 resulted in hospitalization, 4 in death, 5 in life-threatening events), 55 for ruxolitinib (36 resulted in hospitalization, 12 in death, 1 in disability, 5 in life-threatening events), and 3 for extended-release tofacitinib (all resulted in hospitalization).
  • Portal vein thrombosis: 11 unique cases were reported for ruxolitinib (9 cases resulted in hospitalization and 2 in death).
  • Deep vein thrombosis: 18 unique cases for tofacitinib (11 resulted in hospitalization, 3 in death, 1 in disability, and 1 in a life-threatening event), 40 for ruxolitinib (28 resulted in hospitalization, 10 in death, 1 in disability, and 3 in life-threatening events), and 1 for extended-release tofacitinib that did not have a specified outcome.
  • Thrombosis: 43 unique cases for tofacitinib (19 resulted in hospitalization, 2 in death, and 1 in a life-threatening event), 75 for ruxolitinib (43 resulted in hospitalization, 11 in death, 1 in disability, and 2 in life-threatening events), and 5 for extended-release tofacitinib (4 resulted in hospitalization).

Of course there is no event rate here and there is no denominator to know if this is high, low or expected given the patient and disease treated. Hence its curious that these many events were identified post-marketing but not during the drug development for ruxolitinib and tofacitinib.

At the 2017 American College of Rheumatology annual meeting, there were numerous studies that addressed this issue:

  • Genovese et al (Abst #511) showed the baricitinib risk for DVT/PE was 12/1000 Pt years in the first 6 mos and with long term follow up was 5-6 per 1000 PY
  • Mease et al (Abst #16L) reviewed the risk of VTE in the RA, psoriasis, psoriatic arthritis and ulcerative colitis programs and found no VTE events with psoriasis or ulcerative colitis, but noted few events with both 5 mg and 10 mg tofacitinib that appeared to be less than that seen with methotrexate alone.

The risk of VTE with RA and like disorders remains a rare and possible association. Whether this risk is augmented by JAK inhibitors remains to be seen. Hopefully the FDA will further analyze and clarify this issue for all JAK inhibitors.

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

Unproven But Profitable Stem Cell Clinics

Stem cell clinics are popular and proliferating as they are largely a cash business and fall outside of FDA regulatory control. In lieu of scientific proof, most advocates use patient testimonials and the placebo effect to back up their claims.

Out of Pocket Costs for Biosimilars - No Savings So Far

JAMA has published an analysis showing that under Medicare Part D, RA biosimilar infliximab-dyyb was only moderately less expensive (18% less) than the biologic infliximab and, owing to differences in gap discounts, the out of pocket costs for the biosimilar was nearly $1700 more than infliximab in 2017.

Cutting Oral JAK 1/2 Inhibitor Dose an Option in RA

Many patients with rheumatoid arthritis (RA) who achieved sustained disease control with baricitinib (Olumiant) treatment were able to reduce their daily dose from 4 mg to 2 mg and maintain their response, a double-blind substudy of a long-term extension trial found.

Tocilizumab Equals other Biologics in Cardiovascular Risk

An odd side effect of several new agents is the risk of hyperlipidemia. While this has been seen with tocilizumab (TCZ), there does not appear to be a resultant risk of cardiovascular (CV) events. A study of claims data compared CV risk in rheumatoid arthritis (RA) patients receiving TOC (an IL6 receptor antagonists) and other biologics and found no differences with regard to CV outcomes.

Treatment Preferences in Still’s Disease

In July 2018, RheumNow launched a “Live Vote” survey of US and non-US rheumatologists that asked how they diagnose and treat systemic juvenile idiopathic arthritis (sJIA), also known as “Still’s disease”. It appears that many prefer to start therapy with an IL-1 inhibitor, after a course of steroids and MTX/DMARD. Yet, these findings suggest there are significant unmet needs in the diagnosis and management of sJIA patients.